PL1910346T3 - Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny - Google Patents

Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny

Info

Publication number: PL1910346T3
Authority: PL; Poland
Prior art keywords: lactamyl; phenylalanine; cysteine; serine; beta
Prior art date: 2005-07-19

Application number

PL06787593T

Other languages

English (en)

Inventor

Gary A. Koppel

Marvin J. Miller

Original Assignee

Azevan Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-19

Filing date

2006-07-18

Publication date

2019-09-30

2006-07-18 Application filed by Azevan Pharmaceuticals, Inc. filed Critical Azevan Pharmaceuticals, Inc.

2019-09-30 Publication of PL1910346T3 publication Critical patent/PL1910346T3/pl

Links

MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 title 1
-1 Beta-lactamyl phenylalanine Chemical compound 0.000 title 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 title 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 title 1
229940116211 Vasopressin antagonist Drugs 0.000 title 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title 1
235000018417 cysteine Nutrition 0.000 title 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 title 1
239000003038 vasopressin antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Diabetes (AREA)
Immunology (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Anesthesiology (AREA)

PL06787593T 2005-07-19 2006-07-18 Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny PL1910346T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US70067305P	2005-07-19	2005-07-19
EP06787593.0A EP1910346B1 (en)	2005-07-19	2006-07-18	Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
PCT/US2006/027703 WO2007011878A2 (en)	2005-07-19	2006-07-18	Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists

Publications (1)

Publication Number	Publication Date
PL1910346T3 true PL1910346T3 (pl)	2019-09-30

Family

ID=37529732

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06787593T PL1910346T3 (pl)	2005-07-19	2006-07-18	Beta-laktamowy antagonista wazopresyny fenyloalaniny, cysteiny i seryny

Country Status (15)

Country	Link
US (2)	US8048874B2 (pl)
EP (1)	EP1910346B1 (pl)
JP (2)	JP5328349B2 (pl)
KR (2)	KR101521405B1 (pl)
CN (1)	CN101268068B (pl)
AU (1)	AU2006270039B2 (pl)
BR (1)	BRPI0613664B1 (pl)
CA (1)	CA2615813C (pl)
DK (1)	DK1910346T3 (pl)
ES (1)	ES2726942T3 (pl)
PL (1)	PL1910346T3 (pl)
RU (1)	RU2466991C2 (pl)
SI (1)	SI1910346T1 (pl)
TR (1)	TR201907381T4 (pl)
WO (1)	WO2007011878A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002342045C1 (en) *	2001-10-12	2009-07-30	Azevan Pharmaceuticals, Inc.	Beta-lactamyl vasopressin Vla antagonists
US7601695B2 (en)	2003-03-10	2009-10-13	Optimer Pharmaceuticals, Inc.	Antibacterial agents
CN104922117A (zh)	2005-03-22	2015-09-23	阿泽范药品公司	用于治疗月经前病症的β-内酰氨基链烷酸
CA2615813C (en) *	2005-07-19	2015-12-15	Azevan Pharmaceuticals, Inc.	Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2008034032A2 (en) *	2006-09-14	2008-03-20	Azevan Pharmaceuticals, Inc.	Beta-lactam cannabinoid receptor modulators
AU2008316830B2 (en)	2007-10-25	2016-03-17	Cempra Pharmaceuticals, Inc.	Process for the preparation of macrolide antibacterial agents
CN107854477A (zh)	2008-10-24	2018-03-30	森普拉制药公司	使用含三唑的大环内酯治疗抗性疾病的方法
US9937194B1 (en)	2009-06-12	2018-04-10	Cempra Pharmaceuticals, Inc.	Compounds and methods for treating inflammatory diseases
AU2011272738B2 (en)	2010-07-01	2015-08-20	Azevan Pharmaceuticals, Inc.	Methods for treating post traumatic stress disorder
KR20130120458A (ko)	2010-09-10	2013-11-04	셈프라 파마슈티컬스, 인크.	질환을 치료하기 위한 수소결합 형성 플루오로 케토라이드
WO2013148891A1 (en)	2012-03-27	2013-10-03	Cempra Pharmaceuticals, Inc.	Parenteral formulations for administering macrolide antibiotics
WO2014152326A1 (en)	2013-03-14	2014-09-25	Cempra Pharmaceuticals, Inc.	Methods for treating respiratory diseases and formulations therefor
AU2014233240B2 (en)	2013-03-15	2018-08-09	Cempra Pharmaceuticals, Inc.	Convergent processes for preparing macrolide antibacterial agents
BR112016022575A2 (pt)	2014-03-28	2017-08-15	Azevan Pharmaceuticals Inc	Composições e métodos para o tratamento de doenças neurodegenerativas
KR102790657B1 (ko) *	2017-09-15	2025-04-02	아제반 파마슈티칼스, 인코퍼레이티드	뇌 손상을 치료하기 위한 조성물 및 방법

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1422263A (en)	1973-01-30	1976-01-21	Ferrosan As	4-phenyl-piperidine compounds
US4314081A (en)	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
NL7503310A (nl)	1975-03-20	1976-09-22	Philips Nv	Verbindingen met antidepressieve werking.
US4576753A (en) *	1975-10-06	1986-03-18	Fujisawa Pharmaceutical Co., Ltd.	Azetidinone compounds and processes for preparation thereof
GB1526331A (en)	1976-01-14	1978-09-27	Kefalas As	Phthalanes
US4341698A (en) *	1979-06-21	1982-07-27	Richardson-Merrell Inc.	Enkaphalin derivatives
US4536518A (en)	1979-11-01	1985-08-20	Pfizer Inc.	Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS6033439B2 (ja) *	1980-03-07	1985-08-02	財団法人相模中央化学研究所	ジペプチドの製造方法
JPS56125361A (en) *	1980-03-07	1981-10-01	Sagami Chem Res Center	Azetidinone compound
FR2508035A1 (fr)	1981-06-23	1982-12-24	Fabre Sa Pierre	Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en)	1983-10-26	1988-08-02	American Home Products Corporation	Substituted phenylacetamides
US4751299A (en)	1983-11-18	1988-06-14	Takeda Chemical Industries, Ltd.	Optically active β-lactams and method of their production
JPS60112757A (ja) *	1983-11-18	1985-06-19	Takeda Chem Ind Ltd	光学活性β−ラクタム類およびその製造法
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US4734498A (en)	1986-07-10	1988-03-29	Eli Lilly And Company	3β-succinimidoazetidinones as chiral intermediates
US4772694A (en)	1986-07-24	1988-09-20	Eli Lilly And Company	Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en)	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
US5011472A (en)	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
GB9204001D0 (en)	1992-02-25	1992-04-08	Jacobs Suchard Ag	Process for producing reduced fat nuts
AU4713293A (en)	1992-07-13	1994-01-31	Merck Sharp & Dohme Limited	Heterocyclic amide derivatives as tachykinin derivatives
CA2140640A1 (en)	1992-08-13	1994-03-03	David C. Horwell	Tachykinin antagonists
FR2696178B1 (fr)	1992-09-30	1994-12-30	Sanofi Elf	Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
WO1994026735A1 (en)	1993-05-06	1994-11-24	Merrell Dow Pharmaceuticals Inc.	Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists
WO1996035122A1 (en) *	1995-05-03	1996-11-07	Eli Lilly And Company	Combinatorial process for synthesizing azetidinone analogs
US5759865A (en)	1995-05-03	1998-06-02	Eli Lilly And Company	Combinatorial process for synthesizing azetidinone analogs
US6204260B1 (en) *	1996-02-23	2001-03-20	Eli Lilly And Company	Non-peptidyl vasopressin V1a antagonists
US6403632B1 (en)	2000-03-01	2002-06-11	Bristol Myers Squibb Pharma Co	Lactam metalloprotease inhibitors
WO2001012171A2 (en)	1999-08-16	2001-02-22	Revaax Pharmaceuticals, Llc	Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
FR2804114B1 (fr) *	2000-01-25	2002-03-08	Sanofi Synthelabo	Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
GB0019006D0 (en)	2000-08-04	2000-09-20	Astrazeneca Ab	Novel compounds
AU2002342045C1 (en) *	2001-10-12	2009-07-30	Azevan Pharmaceuticals, Inc.	Beta-lactamyl vasopressin Vla antagonists
WO2003051314A2 (en)	2001-12-18	2003-06-26	Medallion Biomedical, Llc	Antibiotic compounds
US7135479B2 (en)	2002-09-12	2006-11-14	Wyeth	Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
KR20060056944A (ko)	2003-07-14	2006-05-25	아레나 파마슈티칼스, 인크.	대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
WO2005035492A1 (en) *	2003-10-03	2005-04-21	Serenix Pharmaceuticals, Llc.	3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS
CN104922117A (zh) *	2005-03-22	2015-09-23	阿泽范药品公司	用于治疗月经前病症的β-内酰氨基链烷酸
CA2615813C (en) *	2005-07-19	2015-12-15	Azevan Pharmaceuticals, Inc.	Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists
WO2008034032A2 (en) *	2006-09-14	2008-03-20	Azevan Pharmaceuticals, Inc.	Beta-lactam cannabinoid receptor modulators

2006
- 2006-07-18 CA CA2615813A patent/CA2615813C/en not_active Expired - Lifetime
- 2006-07-18 KR KR1020147015698A patent/KR101521405B1/ko not_active Expired - Fee Related
- 2006-07-18 RU RU2008106251/04A patent/RU2466991C2/ru active
- 2006-07-18 EP EP06787593.0A patent/EP1910346B1/en not_active Expired - Lifetime
- 2006-07-18 TR TR2019/07381T patent/TR201907381T4/tr unknown
- 2006-07-18 ES ES06787593T patent/ES2726942T3/es not_active Expired - Lifetime
- 2006-07-18 PL PL06787593T patent/PL1910346T3/pl unknown
- 2006-07-18 CN CN200680034276.5A patent/CN101268068B/zh not_active Expired - Fee Related
- 2006-07-18 US US11/996,006 patent/US8048874B2/en active Active
- 2006-07-18 DK DK06787593.0T patent/DK1910346T3/da active
- 2006-07-18 BR BRPI0613664-8A patent/BRPI0613664B1/pt not_active IP Right Cessation
- 2006-07-18 JP JP2008522861A patent/JP5328349B2/ja not_active Expired - Fee Related
- 2006-07-18 SI SI200632330T patent/SI1910346T1/sl unknown
- 2006-07-18 KR KR1020087003252A patent/KR101523776B1/ko not_active Expired - Fee Related
- 2006-07-18 WO PCT/US2006/027703 patent/WO2007011878A2/en not_active Ceased
- 2006-07-18 AU AU2006270039A patent/AU2006270039B2/en not_active Ceased
2011
- 2011-10-31 US US13/285,590 patent/US8426400B2/en not_active Expired - Fee Related
2013
- 2013-03-06 JP JP2013044654A patent/JP2013151520A/ja active Pending

Also Published As

Publication number	Publication date
ES2726942T3 (es)	2019-10-10
BRPI0613664B1 (pt)	2021-08-24
TR201907381T4 (tr)	2019-06-21
US8048874B2 (en)	2011-11-01
CN101268068B (zh)	2015-12-02
DK1910346T3 (da)	2019-05-27
KR101523776B1 (ko)	2015-05-28
US20080280870A1 (en)	2008-11-13
KR20140089430A (ko)	2014-07-14
JP5328349B2 (ja)	2013-10-30
SI1910346T1 (sl)	2019-08-30
US20120220765A1 (en)	2012-08-30
WO2007011878A3 (en)	2007-09-07
EP1910346A2 (en)	2008-04-16
BRPI0613664A8 (pt)	2018-06-19
KR20080036193A (ko)	2008-04-25
KR101521405B1 (ko)	2015-05-18
CN101268068A (zh)	2008-09-17
US8426400B2 (en)	2013-04-23
JP2009502788A (ja)	2009-01-29
CA2615813A1 (en)	2007-01-25
AU2006270039B2 (en)	2013-07-04
CA2615813C (en)	2015-12-15
RU2008106251A (ru)	2009-08-27
JP2013151520A (ja)	2013-08-08
WO2007011878A2 (en)	2007-01-25
EP1910346B1 (en)	2019-02-27
AU2006270039A1 (en)	2007-01-25
BRPI0613664A2 (pt)	2011-01-25
WO2007011878A8 (en)	2007-04-26
RU2466991C2 (ru)	2012-11-20

Publication	Publication Date	Title
IL183308A0 (en)	2007-09-20	Cathepsin cysteine protease inhibitors
PT1981519T (pt)	2018-02-23	Inibição de protéases
IL187463A0 (en)	2008-03-20	Proteasome inhibitors and uses thereof
IL185308A0 (en)	2008-02-09	Replikin peptides and uses thereof
GB0508863D0 (en)	2005-06-08	Peptide
IL182024A0 (en)	2007-07-24	Peptide cyclisation
SI1910346T1 (sl)	2019-08-30	Antagonist beta-laktamil fenilalalina, cisteina in serin vasopresina
GB0513841D0 (en)	2005-08-10	Cysteine protease inhibitors
EP1953227A4 (en)	2010-06-16	BINDER OF LIPOPOLYSACCHARIDE OR LIPID A, AND NEW PEPTIDE
GB0526019D0 (en)	2006-02-01	Peptides
GB0513839D0 (en)	2005-08-10	Cysteine protease inhibitors
GB0513840D0 (en)	2005-08-10	Cysteine protease inhibitors
GB0516527D0 (en)	2005-09-21	Peptides
GB0421319D0 (en)	2004-10-27	Gas detection
GB2432169B (en)	2010-10-13	Underground chamber and well member therefor
ZA200702296B (en)	2008-10-29	Peptide cyclisation
GB0416068D0 (en)	2004-08-18	Carrying case
ZA200709294B (en)	2009-01-28	Peptide
GB0516303D0 (en)	2005-09-14	Peptide
GB0418414D0 (en)	2004-09-22	Peptide
GB0513837D0 (en)	2005-08-10	Cysteine protease inhibitors
GB0513842D0 (en)	2005-08-10	Cysteine protease inhibitors
GB0503093D0 (en)	2005-06-01	Ricin-binding peptide and methods for use thereof
IL160509A0 (en)	2004-07-25	Secondary-electrons detection arrangement
GB0517813D0 (en)	2005-10-12	Peptides and uses thereof